Shares of genomics company Illumina (NASDAQ:ILMN) jumped 3.7% in the pre-market session after analysts at Robert W. Baird increased their price target on the life sciences company's stock to $105.00.

Wall Street expects a year-over-year increase in earnings on higher revenues when CRISPR Therapeutics AG (CRSP) reports ...

Analysts William Tng and Tan Jie Hui believe Venture’s shares could find “support” at their FY2025 book value per share ...

Wall Street watches a company's quarterly report closely to understand as much as possible about its recent performance and what to expect going forward. Of course, one figure often stands out among ...

Figma raised the proposed price range for its U.S. initial public offering on Monday and is now aiming for a valuation of $18 ...

Figma (FIG), a design software company that provides a wide range of artificial intelligence tools for creating and sharing ...

Figma may lead the way for other software companies including Genesys, Canva and Databricks to conduct multibillion-dollar ...

Figma, which plans to sell nearly 12.5 million shares in the IPO, said it now expects a pricing of $30 to $32 a share, up from a previous estimate of $25 to $28 apiece. A pricing at the high end of ...

The company now expects shares to go for $30 to 32 each, up from the range of $25 to $28 that it disclosed on July 21. The new range, announced in a regulatory filing, suggests Figma would be worth ...

Seeking Alpha's roundup of statements, announcements and remarks that could impact the technology sector. Read more here.